Yingying Shen
Overview
Explore the profile of Yingying Shen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
116
Citations
1145
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Huang Y, Zheng Y, Guo Y, Zhang Q, Shen Y, Zhang H, et al.
Nanomaterials (Basel)
. 2025 Feb;
15(4).
PMID: 39997837
Solid-state electrolytes are currently receiving increasing interest due to their high mechanical strength and chemical stability for safe battery construction. However, their poor ion conduction and unclear conduction mechanism need...
2.
Zhao Y, Wu W, Liu K, Shi W, Peng Y, Zhang C, et al.
Food Chem
. 2025 Feb;
476:143469.
PMID: 39986082
Glutelin, the key storage substance for determining rice quality, was sensitive to warming and nitrogen. However, the relationship between the structural properties of glutelin and rice quality needs to be...
3.
Mu Q, Hu F, Shen Y, Zheng Y, Ye X, Liu Y
Arch Dermatol Res
. 2025 Feb;
317(1):338.
PMID: 39899160
Phthalates are commonly found in plastic products, personal care products, and food packaging. In recent years, the relationship between phthalates and skin diseases such as eczema has been gaining attention....
4.
Jin Z, Wang X, Lang Y, Song Y, Zhan H, Shama W, et al.
Alzheimers Res Ther
. 2025 Feb;
17(1):33.
PMID: 39893456
Background: The nature and severity of Alzheimer's disease (AD) pathologies in the retina and brain correspond. However, retinal biomarkers need to be validated in clinical cohorts with confirmed AD biomarkers...
5.
Jiang Y, Shen Y
Front Nutr
. 2025 Jan;
11():1478825.
PMID: 39845910
Background: Dyslipidemia is a major risk factor for cardiovascular disease (CVD) and atherosclerotic CVD (ASCVD). The composite dietary antioxidant index (CDAI), an emerging measure of combined dietary antioxidant exposure, may...
6.
Shen Y, Jiang Y, Wu J, Wang C, Huang J, Liu J, et al.
Anticancer Drugs
. 2025 Jan;
36(4):290-296.
PMID: 39819770
Small cell lung cancer (SCLC) is a highly aggressive form of lung cancer with limited therapeutic options and poor prognosis. In this study, we explored the therapeutic potential of BGJ398,...
7.
Chen X, Zeng Q, Yin L, Yan B, Wu C, Feng J, et al.
Cell Death Dis
. 2025 Jan;
16(1):8.
PMID: 39788945
This research demonstrates that DCC-2036 (Rebastinib), a potent third-generation tyrosine kinase inhibitor (TKI), effectively suppresses tumor growth in colorectal cancer (CRC) models with functional immune systems. The findings underscore the...
8.
Chen W, Shen Y, Song S, Li X
Eur J Med Res
. 2025 Jan;
30(1):2.
PMID: 39754244
Background: Sleep disturbance is a common concern among stroke survivors, yet the association of sleep duration and sleep disorders with post-stroke depression and all-cause and cardiovascular disease (CVD) mortality remains...
9.
Shen Y, Wang H, Ma Z, Hao M, Wang S, Li J, et al.
Cell Mol Gastroenterol Hepatol
. 2025 Jan;
19(5):101454.
PMID: 39743020
Background & Aims: Sora is the first-line drug for advanced hepatocellular carcinoma (HCC). However, acquired resistance to Sora treatment largely hinders its therapeutic efficacy, and the mechanisms underlying Sora resistance...
10.
Li X, Liu Q, Dong J, Hong Y, Xin C, Guo J, et al.
Ann Med
. 2024 Dec;
57(1):2446689.
PMID: 39731480
Objectives: Platelet transfusion refractoriness (PTR) is a frustrating clinical problem, and primary and persistent (P/P) PTR who experienced persistent PTR since the first transfusion was failed to be well recognized....